None

None

evidence of covid-19 infection within 21 days of vaccination visit history of antibody agent or convalescent plasma for treatment or prevention of covid-19 within 90 days individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of an mrna covid-19 vaccination history of underlying immune disorder. pregnancy immunocompromised participants with primary or acquired immunodeficiency participants on anti-rejection therapy following solid organ transplant or bone marrow transplant participants on biologic therapeutic agents participants with malignancy and ongoing or recent chemotherapy participants receiving systemic immunosuppressive therapy, including corticosteroids equivalent to 20 mg/day of prednisone for 2 weeks participants with chronic kidney disease stage 3 or higher participants with history of significant pulmonary compromise

evidence of covid-19 infection within 21 days of vaccination visit history of antibody agent or convalescent plasma for treatment or prevention of covid-19 within 90 days individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of an mrna covid-19 vaccination history of underlying immune disorder. pregnancy immunocompromised participants with primary or acquired immunodeficiency participants on anti-rejection therapy following solid organ transplant or bone marrow transplant participants on biologic therapeutic agents participants with malignancy and ongoing or recent chemotherapy participants receiving systemic immunosuppressive therapy, including corticosteroids equivalent to 20 mg/day of prednisone for 2 weeks participants with chronic kidney disease stage 3 or higher participants with history of significant pulmonary compromise

evidence of covid-19 infection within 21 days of vaccination visit history of antibody agent or convalescent plasma for treatment or prevention of covid-19 within 90 days individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of pfizer-biontech mrna covid-19 vaccination history of underlying immune disorder. pregnancy immunocompromised participants with primary or acquired immunodeficiency participants on anti-rejection therapy following solid organ transplant or bone marrow transplant participants on biologic therapeutic agents participants with malignancy and ongoing or recent chemotherapy participants receiving systemic immunosuppressive therapy, including corticosteroids equivalent to 20 mg/day of prednisone for 2 weeks participants with chronic kidney disease stage 3 or higher participants with history of significant pulmonary compromise

evidence of covid-19 infection within 21 days of vaccination visit history of antibody agent or convalescent plasma for treatment or prevention of covid-19 within 90 days individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of pfizer-biontech mrna covid-19 vaccination history of underlying immune disorder. pregnancy immunocompromised participants with primary or acquired immunodeficiency participants on anti-rejection therapy following solid organ transplant or bone marrow transplant participants on biologic therapeutic agents participants with malignancy and ongoing or recent chemotherapy participants receiving systemic immunosuppressive therapy, including corticosteroids equivalent to 20 mg/day of prednisone for 2 weeks participants with chronic kidney disease stage 3 or higher participants with history of significant pulmonary compromise